Stock Track | AxoGen Plunges 25% Pre-Market as Sales Disappoint, Outlook Muted

Stock Track

Feb 26, 2025

AxoGen Inc. (AXGN) shares plummeted over 25% in pre-market trading on Wednesday following the company's fourth quarter results that missed expectations and a muted outlook for 2025.

The medical technology company focused on peripheral nerve repair reported revenue of $49.4 million for the fourth quarter of 2024, representing a 15.1% increase over the prior year. While this showed continued growth, it fell short of analysts' estimates.

Looking ahead, AxoGen provided full-year 2025 revenue guidance of 15-17% growth, which disappointed investors hoping for a more robust outlook after the company outlined an ambitious strategic plan targeting a 15-20% revenue CAGR over the next four years. Key growth initiatives included expanding in breast reconstruction, accelerating adoption in extremities and oral/maxillofacial markets, and developing new markets like nerve repair for prostatectomy procedures.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163522199"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163522199\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163522199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163522199","market":"hk","top_or_hot":-1,"title":"Stock Track | AxoGen Plunges 25% Pre-Market as Sales Disappoint, Outlook Muted","media":"Stock Track","content":"<p>AxoGen Inc. (AXGN) shares plummeted over 25% in pre-market trading on Wednesday following the company's fourth quarter results that missed expectations and a muted outlook for 2025.</p>\n\n<p>The medical technology company focused on peripheral nerve repair reported revenue of $49.4 million for the fourth quarter of 2024, representing a 15.1% increase over the prior year. While this showed continued growth, it fell short of analysts' estimates.</p>\n\n<p>Looking ahead, AxoGen provided full-year 2025 revenue guidance of 15-17% growth, which disappointed investors hoping for a more robust outlook after the company outlined an ambitious strategic plan targeting a 15-20% revenue CAGR over the next four years. Key growth initiatives included expanding in breast reconstruction, accelerating adoption in extremities and oral/maxillofacial markets, and developing new markets like nerve repair for prostatectomy procedures.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AxoGen Plunges 25% Pre-Market as Sales Disappoint, Outlook Muted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AxoGen Plunges 25% Pre-Market as Sales Disappoint, Outlook Muted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AxoGen Inc. (AXGN) shares plummeted over 25% in pre-market trading on Wednesday following the company's fourth quarter results that missed expectations and a muted outlook for 2025.</p>\n\n<p>The medical technology company focused on peripheral nerve repair reported revenue of $49.4 million for the fourth quarter of 2024, representing a 15.1% increase over the prior year. While this showed continued growth, it fell short of analysts' estimates.</p>\n\n<p>Looking ahead, AxoGen provided full-year 2025 revenue guidance of 15-17% growth, which disappointed investors hoping for a more robust outlook after the company outlined an ambitious strategic plan targeting a 15-20% revenue CAGR over the next four years. Key growth initiatives included expanding in breast reconstruction, accelerating adoption in extremities and oral/maxillofacial markets, and developing new markets like nerve repair for prostatectomy procedures.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXGN","symbol_name":"AxoGen Inc.","start_time":0,"source_url":"","article_id":"1163522199","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163522199","pubTimestamp":1740561267,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AxoGen Inc.  shares plummeted over 25% in pre-market trading on Wednesday following the company's fourth quarter results that missed expectations and a muted outlook for 2025.The medical technology company focused on peripheral nerve repair reported revenue of $49.4 million for the fourth quarter of 2024, representing a 15.1% increase over the prior year. While this showed continued growth, it fell short of analysts' estimates.Looking ahead, AxoGen provided full-year 2025 revenue guidance of 15-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXGN":"AxoGen Inc."},"translate_title":"由于销售令人失望，前景黯淡，股票赛道AxoGen盘前暴跌25%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":1},"content_text":"AxoGen Inc. (AXGN) shares plummeted over 25% in pre-market trading on Wednesday following the company's fourth quarter results that missed expectations and a muted outlook for 2025.\nThe medical technology company focused on peripheral nerve repair reported revenue of $49.4 million for the fourth quarter of 2024, representing a 15.1% increase over the prior year. While this showed continued growth, it fell short of analysts' estimates.\nLooking ahead, AxoGen provided full-year 2025 revenue guidance of 15-17% growth, which disappointed investors hoping for a more robust outlook after the company outlined an ambitious strategic plan targeting a 15-20% revenue CAGR over the next four years. Key growth initiatives included expanding in breast reconstruction, accelerating adoption in extremities and oral/maxillofacial markets, and developing new markets like nerve repair for prostatectomy procedures.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}